WallStreetZenWallStreetZen

NASDAQ: PHXM
Phaxiam Therapeutics Sa Stock

$4.52-0.33 (-6.8%)
Updated Dec 8, 2023
PHXM Price
$4.52
Fair Value Price
N/A
Market Cap
$14.85M
52 Week Low
$3.00
52 Week High
$14.00
P/E
-1.21x
P/B
0.38x
P/S
3.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.35M
Earnings
-$12.53M
Gross Margin
100%
Operating Margin
-232.3%
Profit Margin
-191%
Debt to Equity
0.79
Operating Cash Flow
-$25M
Beta
0.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PHXM Overview

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHXM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PHXM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHXM is good value based on its book value relative to its share price (0.38x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
PHXM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHXM due diligence checks available for Premium users.

Be the first to know about important PHXM news, forecast changes, insider trades & much more!

PHXM News

Valuation

PHXM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.21x
Industry
11.7x
Market
31.32x

PHXM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
5.42x
PHXM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PHXM's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PHXM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PHXM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$72.0M
Liabilities
$31.8M
Debt to equity
0.79
PHXM's short-term assets ($32.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHXM's short-term assets ($32.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHXM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
PHXM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PHXM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PHXM$14.85M-6.80%-1.21x0.38x
ORGS$14.66M+0.66%0.51x1.18x
AZTR$15.24M+28.57%N/A2.86x
HEPA$14.36M+8.17%-0.26x0.89x
MBIO$14.19M-0.65%-0.19x3.54x

Phaxiam Therapeutics Sa Stock FAQ

What is Phaxiam Therapeutics Sa's quote symbol?

(NASDAQ: PHXM) Phaxiam Therapeutics Sa trades on the NASDAQ under the ticker symbol PHXM. Phaxiam Therapeutics Sa stock quotes can also be displayed as NASDAQ: PHXM.

If you're new to stock investing, here's how to buy Phaxiam Therapeutics Sa stock.

What is the 52 week high and low for Phaxiam Therapeutics Sa (NASDAQ: PHXM)?

(NASDAQ: PHXM) Phaxiam Therapeutics Sa's 52-week high was $14.00, and its 52-week low was $3.00. It is currently -67.71% from its 52-week high and 50.67% from its 52-week low.

How much is Phaxiam Therapeutics Sa stock worth today?

(NASDAQ: PHXM) Phaxiam Therapeutics Sa currently has 3,284,500 outstanding shares. With Phaxiam Therapeutics Sa stock trading at $4.52 per share, the total value of Phaxiam Therapeutics Sa stock (market capitalization) is $14.85M.

Phaxiam Therapeutics Sa stock was originally listed at a price of $247.50 in Nov 10, 2017. If you had invested in Phaxiam Therapeutics Sa stock at $247.50, your return over the last 6 years would have been -98.17%, for an annualized return of -48.68% (not including any dividends or dividend reinvestments).

How much is Phaxiam Therapeutics Sa's stock price per share?

(NASDAQ: PHXM) Phaxiam Therapeutics Sa stock price per share is $4.52 today (as of Dec 8, 2023).

What is Phaxiam Therapeutics Sa's Market Cap?

(NASDAQ: PHXM) Phaxiam Therapeutics Sa's market cap is $14.85M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Phaxiam Therapeutics Sa's market cap is calculated by multiplying PHXM's current stock price of $4.52 by PHXM's total outstanding shares of 3,284,500.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.